Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Sides With Amneal Over Inhaler Patent Dispute With Teva

FTC’s Amicus Brief Called Teva’s Arguments “Unavailing And Inconsistent With The Statute”

Executive Summary

After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.

You may also be interested in...

GSK Is Third Major Inhaler Maker To Cap Copays; Will Teva Follow?

It might make sense from a competitive standpoint for Teva to join the trend. That’s the way it happened in the insulin category.

'America First’ Non-Profit Points To USPTO And FDA For Patent Abuse

The America First Policy Institute has blamed patent abuse for drug unaffordability, poking holes in governmental institutions and their current systems.

US Senator Calls Out Big Pharma Over Improper Inhaler Patents

US Senator Baldwin’s letters to four inhaler manufacturers come after the FTC challenged their patents last year, but the companies rejected patent amendment claims.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts